Clinical Trials Logo
  1. Home
  2. Advanced NSCLC
  3. NCT03074175

Plasma miRNAs Predict Radiosensitivity of Different Fractionation Regimes in Palliative Radiotherapy for Advanced Non-small Cell Lung Cancer：Multicenter Controlled Study.(RadmiR-01)

Advanced Nsclc Clinical Trial

Official title:
Plasma miRNAs Predict Radiosensitivity of Different Fractionation Regimes in Palliative Radiotherapy for Advanced Non-small Cell Lung Cancer：Multicenter Controlled Study.

Clinical Trial Summary

Lung cancer is a malignant tumor that causes the highest morbidity and mortality, and the main pathological type is non-small cell lung cancer (NSCLC). Most of them present with advanced stage at diagnosis. Radiotherapy is an important treatment strategy for advanced non-small cell lung cancer. However patients have different responses to radiotherapy due to individual differences, thus there is still lacking of sensitive markers to predict treatment response at present. Using bioinformatics to process the data and small sample clinical trial, our previous study found 5 plasma miRNAs were related to radiosensitivity. The design is controlled clinical trial. According to the size of lung lesions, the investigators divided the patients into hyperfractionated radiotherapy group（50Gy/11F/2W) with lesion ≤5cm in diameter and conventional fractionated radiotherapy group（60Gy/30F/6W）with lesion >5cm in diameter.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03074175
Study type Interventional
Source Xinqiao Hospital of Chongqing
Contact
Status Completed
Phase N/A
Start date July 1, 2017
Completion date December 31, 2019
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT02133196 - T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer Phase 2
Recruiting NCT00813332 - Second-line Therapy Study of Combined Chemotherapy and Endostar to Patients With Non-Small Cell Lung Cancer(NSCLC) Phase 4
Completed NCT03215810 - Nivolumab and Tumor Infiltrating Lymphocytes (TIL) in Advanced Non-Small Cell Lung Cancer Phase 1
Recruiting NCT04982224 - Study of REGN5093-M114 (METxMET Antibody-Drug Conjugate) in Adult Patients With Mesenchymal Epithelial Transition Factor (MET) Overexpressing Advanced Cancer Phase 1/Phase 2
Not yet recruiting NCT04992858 - Ningetinib in Advanced NSCLC Skipping Mutations With MET Exon 14 Skipping Mutations Phase 2
Active, not recruiting NCT03127449 - AST2818 in Advanced Non-Small Cell Lung Cancer With EGFR Mutations N/A
Recruiting NCT05609578 - Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation Phase 2
Not yet recruiting NCT06356675 - A Single-arm Pilot Study of Tislelizumab Combined With Anlotinib in Patients With Advanced NSCLC With Driver-negative After Progression to Immunotherapy Phase 4
Terminated NCT05106335 - A Study to Evaluate Camrelizumab Combined With Famitinib as Subsequent Therapy in Patients With Advanced NSCLC Phase 3
Not yet recruiting NCT04229121 - Clinical Sensitivity Verification Study of Circulating Tumor Cells Gene Mutation Detection From Advanced NSCLC Patients
Recruiting NCT05219162 - Real-World Study on Gene Profile in Patients With Advanced NSCLC Who Progressed on First-Line Osimertinib Therapy(GPS). Phase 4
Not yet recruiting NCT05859217 - A Study of Combining Cabozantinib and Atezolizumab for Advanced/Metastatic NSCLC (Cabatezo-1) Phase 2
Recruiting NCT03062800 - Study of Thalidomide in Treatment of Advanced Nsclc (Dream-003) Phase 2
Completed NCT02055508 - POSITIVE - Study (Part III) Heidelberg N/A
Active, not recruiting NCT04043195 - Nivolumab and Ipilimumab in Combination With Immunogenic Chemotherapy for Patients With Advanced NSCLC Phase 1/Phase 2